May 2026
đź“Ł VC round data is live. Check it out!
Largest Medical Devices Public Companies in the UK
Benchmark revenue and EBITDA valuation multiples for public comps like
Halma, Smith & Nephew, Renishaw, Convatec Group and Oxford Nanopore Technologies.
 | Halma consists of 45 operating businesses managed in a decentralized manner. The company, through its products, focuses on trying to make the world safer, cleaner and healthier. The group operates across three segments: safety, environmental and analysis, and medical equipment. Halma’s products include smoke detectors, healthcare equipment, door sensors, and water treatment. Most of the group’s products are niche with limited competition. Over 75% of sales are generated in the United States, Europe and United Kingdom. Halma is listed on the London Stock Exchange. | $64 | +49% | $24B | $25B | 8.2x | 33.5x | ||
| Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder. | $15 | -1% | $13B | $15B | 2.5x | 9.6x | ||
| Renishaw Plc is an engineering company specializing in precision measurement and healthcare technologies. It operates in two reporting segments: Manufacturing technologies, and Analytical instruments and medical devices. Its products include coordinate measuring machines, machine tool probes, metal 3D printers, neurosurgical systems, and dental technologies. The company generates the majority of its revenue from exporting these products to the markets in countries like China, the USA, Japan, and Germany. Renishaw has operations in several countries and focuses on research, development, and manufacturing prominently in the UK, Ireland, and India. The company serves diverse industrial and healthcare sectors. | $72 | +87% | $5B | $5B | 5.1x | 22.8x | ||
| Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue. | $3 | -32% | $5B | $7B | 2.7x | 10.1x | ||
| Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. | $2 | +0% | $2B | $1B | 5.0x | (12.9x) | ||
| Advanced Medical Solutions Group PLC is engaged in developing, and manufacturing advanced wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical; and Woundcare, of which Surgical segment derives maximum revenue. | $3 | +1% | $636M | $721M | 2.3x | 10.9x | ||
| The Beauty Tech Group PLC operates in the at-home beauty technology market. The company includes three beauty technology brands - CurrentBody Skin, ZIIP Beauty and Tria Laser. It develops, manufactures, and sells beauty devices designed for home use, incorporating technologies such as LED light, radiofrequency, microcurrent, and laser-based treatments. The company distributes its products in the UK and internationally through direct-to-consumer e-commerce channels and selected retail partners. | $5 | -- | $479M | $429M | 2.3x | 8.5x | ||
| NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world. | $1 | -14% | $329M | $303M | 4.6x | 13.6x | ||
| Deltex Medical Group PLC is a British manufacturer of Fluid Management devices, which include the ODM and now ODM+ haemodynamic monitoring systems. The company has developed the gold standard for haemodynamic monitoring with oesophageal Doppler technology, which is marketed as TrueVue Doppler and often generically referred to by clinicians as ODM. The company's initial and principal technology is Doppler-based ultrasound oesophageal haemodynamic monitoring. | $0 | -- | $181M | $183M | - | - | ||
| EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements. | $0 | +0% | $154M | $138M | 2.0x | 8.1x | ||
| SDI Group PLC designs and manufactures scientific and technology products for use by the life science, healthcare, astronomy, consumer manufacturing, and art conservation markets through Synoptics, the Artemis, the Opus instruments, and Astles Control systems brands. The Digital Imaging segment incorporates the Synoptics brands Syngene, Synbiosis, Synoptics Health and Fistreem, the Atik brands Atik Cameras, Opus, and Quantum Scientific Imaging, and the Graticules Optics business. The Sensors & Control segment combines Sentek, Astles Control Systems, Applied Thermal Control, Thermal Exchange, MPB Industries, and Chell Instruments businesses. It operates in the UK, Europe, America, Rest of Asia, and Rest of the world segments. It derives majority of its revenues from the United Kingdom. | $1 | -4% | $116M | $149M | 1.7x | 9.2x | ||
| Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world. | $0 | +6% | $84M | $73M | 13.6x | (2.1x) | ||
| Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world. | $0 | -- | $41M | $37M | 3.2x | (10.8x) | ||
| Carclo PLC is a technology-led plastics group that is engaged in three segments: CTP, Aerospace, and Central. The CTP segment supplies value-adding engineered solutions for the life sciences, optical, and precision component industries. This business operates internationally in a fast-growing and dynamic market underpinned by rapid technological development. The Aerospace segment supplies systems to the manufacturing and aerospace industries. The Central segment relates to central costs and non-trading companies. Geographically, it operates in the regions of the UK, Rest of Europe, North America and Rest of the world. | $0 | -- | $35M | $68M | 0.4x | 3.0x | ||
| Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the precise measurement of clinical outcomes in neurological disorders. Geographically, it derives majority of its revenue from the United States of America and also has a presence in the United Kingdom, European Union, and Rest of world. The company services include Neuroscience consultancy, Technical consultancy, Study design, Data analysis, Study management, Data management, and Reports and interpretation. | $0 | +16% | $23M | $23M | 1.8x | (33.9x) | ||
| Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline. | $0 | -75% | $11M | $10M | 3.4x | (0.5x) | ||
| Median | $1 | +0% | $255M | $243M | 2.7x | 8.5x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Recent Insights
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.